The American College of Cardiology Meeting: Nexlotol, Push Ablation and More!

Thank you for your support during the Reversing Heart Disease Summit. The event has now concluded, but you can still view the content by registering and purchasing the videos, transcripts, and audio files, which you can keep forever. Click Here for more information. This week, Dr. Kahn is focusing on exciting new results announced at the American College of Cardiology. A new oral cholesterol medication (PCKS9 inhibitor) from Merck looks very promising, and there is a buzz around a new strategy for Afib ablation. However, the biggest ripple was caused by an outcomes study of a non-statin medication called bempedoic acid or Nexletol in patients who are unable to take statins. This study is a great victory for providing more tools in the toolbox of advanced heart care.